<DOC>
	<DOCNO>NCT01481545</DOCNO>
	<brief_summary>The purpose study evaluate use chemotherapy , radiation therapy bevacizumab surgery patient locally advanced rectal cancer ( LARC ) .</brief_summary>
	<brief_title>Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy Patients With Poor-Risk Rectal Cancer</brief_title>
	<detailed_description>To determine pathological complete response ( pCR-TRG1 ) rate patient treat 2 different schedule bevacizumab plus primary chemotherapy radiotherapy pelvic region optimal surgery apply . Bevacizumab give intravenous infusion dose 5 mg/kg concurrent chemotherapy radiotherapy every 2 week 4 cycle -14 day start chemo-radiotherapy ( classical schedule ) 4 day concurrent administration chemotherapy radiation therapy 2 cycle number TRG1 reach first stage classical schedule Simon 's method use calculate sample size.Setting b error 0.05 0.20 , respectively , define minimum activity interest ( p0 ) TRG1 rate=30 % . In order demonstrate TRG1 rate ≥50 % ( p1 ) , least 6 TRG1 first 15 patient , least 19 TRG1 total 46 patient report first second stage , respectively .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients histologically cytologically confirm diagnosis locally advanced rectal cancer ( LARC ) high risk recurrence ( T4 , N+ , T3N0 tumor locate low third rectum and/or circumferential resection margin ( CRM ) £5 mm ) , LARC resectable organ metastasis ( M1 ) . Age 18 year old Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Life expectancy least 12 week Measurable and/or evaluable ( resectable organ metastasis ) lesion accord RECIST criterion Neutrophils &gt; 1500 Platelets &gt; 100,000 /L Total bilirubin &lt; = 1.5 time uppernormal limit ( UNL ) Institutional normal value ASAT ( SGOT ) and/or ALAT ( SGPT ) &lt; = 2.5 x UNL , &lt; = 5 x UNL case liver metastasis , alkaline phosphatase &lt; = 2.5 x UNL , &lt; = 5 x UNL case liver metastasis . Creatinine clearance &gt; 50 mL/min serum creatinine &lt; = 1.5 x UNL Urine dipstick proteinuria &lt; 2+ . Patients discover &gt; = 2+ proteinuria dipstick urinalysis baseline , undergo 24hour urine collection must demonstrate &lt; = 1 g protein/24 hr . Written informed consent . Patients must accessible treatment follow . Patients register trial must treat follow participate Center Prior radiotherapy chemotherapy rectal cancer . Untreated brain metastasis spinal cord compression primary brain tumour History evidence upon physical examination CNS disease unless adequately treat ( e.g. , seizure control standard medical therapy history stroke ) . History inflammatory bowel disease and/or acute/subacute bowel occlusion Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy . Uncontrolled hypertension Clinically significant ( i.e . active ) cardiovascular disease , example cerebrovascular accident ( ≤ 6 month ) , myocardial infarction ( ≤ 6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose . Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration . Treatment investigational drug within 30 day prior enrolment . Patients know allergy Chinese hamster ovary cell protein , component study medication Other coexist malignancy malignancy diagnose within last 5 year exception basal squamous cell carcinoma cervical cancer situ Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study . Pregnant lactate woman . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>locally advanced</keyword>
	<keyword>high risk</keyword>
	<keyword>preoperative therapy</keyword>
</DOC>